Management of acute attacks of hereditary angioedema: potential role of icatibant
Management of acute attacks of hereditary angioedema: potential role of icatibant
About this item
Full title
Author / Creator
Publisher
New Zealand: Taylor & Francis Ltd
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Taylor & Francis Ltd
Subjects
More information
Scope and Contents
Contents
Icatibant (Firazyr(®)) is a novel subcutaneous treatment recently licensed in the European Union for acute hereditary angioedema. Hereditary angioedema, resulting from inherited partial C1 inhibitor deficiency, is a disabling condition characterized by intermittent episodes of bradykinin-mediated angioedema. Icatibant blocks bradykinin B2 receptors...
Alternative Titles
Full title
Management of acute attacks of hereditary angioedema: potential role of icatibant
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_8cd8973f24f443408aa0c88a3bde9b70
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8cd8973f24f443408aa0c88a3bde9b70
Other Identifiers
ISSN
1178-2048,1176-6344
E-ISSN
1178-2048
DOI
10.2147/vhrm.s4332
